Cantor Fitzgerald raised the firm’s price target on Palvella Therapeutics (PVLA) to $210 from $200 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer
- Palvella Therapeutics price target raised to $212 from $122 at Lucid Capital
- Palvella Therapeutics Reports Positive Phase 2 Study Results
- Palvella Therapeutics announces topline results from Phase 2 TOIVA trial
- Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments in DSAP Treatment